Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-HYNIC-Tyr3-octreotide
- Development stage
- Unknown
- Lead developer
- National Centre for Nuclear Research
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
99mTc-HYNIC-Tyr3-octreotide is a radiopharmaceutical imaging agent used for the detection and staging of tumors that overexpress somatostatin receptors (SSTRs). It consists of the somatostatin analog [Tyr3]octreotide (TOC) conjugated to the bifunctional chelator hydrazinonicotinamide (HYNIC). The complex is typically stabilized with co-ligands such as ethylenediamine-N,N'-diacetic acid (EDDA) or tricine and labeled with the gamma-emitting radioisotope technetium-99m. The drug acts as a high-affinity agonist for somatostatin receptor subtype 2 (SSTR2), which is frequently overexpressed in neuroendocrine tumors (NETs) and other malignancies like hepatocellular carcinoma. Following intravenous administration, the agent localizes to receptor-positive tissues, allowing for high-resolution visualization via Single Photon Emission Computed Tomography (SPECT) or SPECT/CT. It is favored over older agents like 111In-pentetreotide due to its superior image quality, lower radiation burden, and more efficient clinical workflow.
- Brand names
- Tektrotyd
- Other names
- 99mTc-HYNIC-octreotide99mTc-labeled [Tyr3]octreotideTechnetium Tc 99m EDDA/HYNIC-Tyr3-octreotide99mTc-EDDA/HYNIC-Tyr3-octreotide
02
Targets
SSTR5 (Somatostatin receptor 5)SSTR3 (Somatostatin receptor 3)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 99mTc-HYNIC-Tyr3-octreotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-HYNIC-Tyr3-octreotide.